SEALSQ Corp (LAES) shareholders
Close on Nov 17, 2026Market cap $207.81MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CVI Investments, Inc. Joint filing with Heights Capital Management, Inc. (9.90%) | 24,377,058 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Heights Capital Management, Inc. Joint filing with CVI Investments, Inc. (9.90%) | 19,689,323 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Tony Moore Joint filing with Anson Funds Management LP (5.60%), Anson Management GP LLC (5.60%) and 3 more | 12,457,698 | 5.60% | 13G (passive) | Mar 31, 2026 |
| Susquehanna Securities, LLC | 12,134,793 | 5.40% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LAES | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| UBS Group AG | 1,361,471 | 0.71% | $4.29M | +428,080 | 0.00% |
| Bank of New York Mellon Corp | 1,242,296 | 0.65% | $3.91M | +1,124,462 | 0.00% |
| Hrt Financial LP | 1,131,645 | 0.59% | $3.56M | +420,076 | 0.00% |
| Two Sigma Investments, LP | 1,103,028 | 0.58% | $3.47M | New | 0.00% |
| Kessler Investment Group, LLC | 975,458 | 0.51% | $3.07M | −18,321 | 1.31% |
| Barclays PLC | 514,556 | 0.27% | $1.62M | New | 0.00% |
| Tudor Investment Corp Et Al | 484,909 | 0.25% | $1.53M | New | 0.00% |
| Man Group plc | 367,260 | 0.19% | $1.16M | New | 0.00% |
| SBI Securities Co., Ltd. | 331,008 | 0.17% | $1.04M | +77,693 | 0.02% |
| XTX Topco Ltd | 323,249 | 0.17% | $1.02M | +269,453 | 0.01% |
| WIM INVESTMENT MANAGEMENT Ltd | 229,600 | 0.12% | $723.24K | New | 0.24% |
| Goldman Sachs Group Inc | 215,800 | 0.11% | $679.77K | +141,893 | 0.00% |
| Headlands Technologies LLC | 199,989 | 0.10% | $629.97K | New | 0.07% |
| Squarepoint Ops LLC | 179,854 | 0.09% | $566.54K | +99,924 | 0.00% |
| Virtu Financial LLC | 176,009 | 0.09% | $554.00K | +91,418 | 0.02% |
| Vident Advisory, LLC | 170,752 | 0.09% | $537.87K | +9,272 | 0.00% |
| LPL Financial LLC | 159,446 | 0.08% | $502.26K | +88,908 | 0.00% |
| Citigroup Inc | 158,471 | 0.08% | $499.18K | +99,478 | 0.00% |
| BlackRock, Inc. | 152,173 | 0.08% | $479.35K | +126,599 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 138,946 | 0.07% | $438.00K | +60,592 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 109 | 12M | 6.4% | 40 / 40 | 16 / 14 | 7M | 30M |
| Q1 2026 | 85 | 35M | 18.5% | 13 / 25 | 31 / 26 | 31M | 5M |
| Q4 2025 | 99 | 10M | 5.1% | 47 / 33 | 12 / 17 | 7M | 3M |
| Q3 2025 | 71 | 5M | 2.8% | 36 / 15 | 10 / 18 | 2M | 4M |
| Q2 2025 | 53 | 7M | 3.7% | 23 / 14 | 7 / 9 | 4M | 2M |
| Q1 2025 | 39 | 4M | 2.2% | 23 / 9 | 2 / 5 | 3M | 1M |
| Q4 2024 | 21 | 3M | 1.5% | 16 / 3 | 0 / 1 | 3M | 0M |
| Q3 2024 | 6 | 0M | 0.0% | 2 / 0 | 2 / 4 | 0M | 1M |
| Q2 2024 | 9 | 1M | 0.4% | 3 / 0 | 1 / 2 | 0M | 0M |
| Q1 2024 | 8 | 1M | 0.5% | 4 / 1 | 0 / 3 | 1M | 0M |
| Q4 2023 | 8 | 0M | 0.0% | 3 / 1 | 2 / 4 | 0M | 0M |
| Q3 2023 | 9 | 0M | 0.1% | 3 / 3 | 2 / 6 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carlos Moreira | Chief Executive Officer, Director | 1,453,549 | 0.76% | Nov 17, 2026 |
| John Charles O'Hara | Chief Financial Officer, Director | 250,435 | 0.13% | Jun 5, 2026 |
| Jean-Pierre Enguent | Vice President, R&DSS | 0 | – | Nov 3, 2026 |
| Alexander Sebastian Hirsch | Chief Marketing Officer | – | – | Aug 26, 2026 |
| Daniel Frederic Alexandre Brau | Chief Quantum Officer | – | – | Aug 17, 2026 |
| Franck Jean Buonanno | Vice-President, Global Sales | 10,000 | 0.01% | May 15, 2026 |
| Moreira Andreas Feuardent | Chief Innovation Officer | 17,466 | 0.01% | Apr 8, 2026 |
| Nathalie Claude Odile Verjus | Company Secretary | 185,004 | 0.10% | Mar 19, 2026 |
| Loic Jean-Claude Hamon | COO SEALSQ USA | – | – | Mar 18, 2026 |
| Jean-Luc Pierre-Marie Triouleyre | General Manager, IC'Alps | – | – | Mar 18, 2026 |
| Bernard Vian | General Manager, SEALSQ France | – | – | Mar 18, 2026 |
| David Alexander Fergusson | Director | 1,581 | 0.00% | Oct 6, 2026 |
| Peter Ward | Director | 270,557 | 0.14% | Oct 6, 2026 |
| Eric Adrien Pellaton | Director | 3,087 | 0.00% | Oct 6, 2026 |
| Ruma Bose | Director | – | – | Mar 19, 2026 |
| Cristina Dolan | Director | 85,081 | 0.04% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Carlos Moreira Chief Executive Officer, Director | Nov 13, 2026 | Tax withholding | −856,514 | $1.25 | $1.07M | 1,445,927 |
| Carlos Moreira Chief Executive Officer, Director | Nov 13, 2026 | Option exercise | +1,606,226 | $0.01 | $16.06K | 2,302,441 |
| Jean-Pierre Enguent Vice President, R&DSS | Nov 3, 2026 | Sale(10b5-1 plan) | −35,000 | $1.38 | $48.33K | 0 |
| Jean-Pierre Enguent Vice President, R&DSS | Nov 2, 2026 | Option exercise | +20,000 | $0.01 | $200 | 35,000 |
| Jean-Pierre Enguent Vice President, R&DSS | Nov 2, 2026 | Option exercise | +15,000 | $0.01 | $150 | 15,000 |
| Jean-Pierre Enguent Vice President, R&DSS | Oct 6, 2026 | Sale(10b5-1 plan) | −35,000 | $2.46 | $85.94K | 0 |
| Jean-Pierre Enguent Vice President, R&DSS | Oct 5, 2026 | Option exercise | +35,000 | $0.01 | $350 | 35,000 |
| Jean-Pierre Enguent Vice President, R&DSS | Sep 3, 2026 | Sale(10b5-1 plan) | −15,000 | $2.40 | $36.00K | 0 |
| Jean-Pierre Enguent Vice President, R&DSS | Sep 1, 2026 | Option exercise | +15,000 | $0.01 | $150 | 15,000 |
| Jean-Pierre Enguent Vice President, R&DSS | Aug 5, 2026 | Sale(10b5-1 plan) | −15,000 | $2.46 | $36.90K | 0 |
| Jean-Pierre Enguent Vice President, R&DSS | Aug 3, 2026 | Option exercise | +15,000 | $0.01 | $150 | 15,000 |
| Jean-Pierre Enguent Vice President, R&DSS | Jul 8, 2026 | Sale(10b5-1 plan) | −15,000 | $2.82 | $42.30K | 0 |
| Jean-Pierre Enguent Vice President, R&DSS | Jul 6, 2026 | Option exercise | +15,000 | $0.01 | $150 | 15,000 |
| Peter Ward Director | Jun 16, 2026 | Tax withholding | −96,530 | $3.07 | $296.35K | 270,531 |
| Peter Ward Director | Jun 16, 2026 | Option exercise | +366,746 | $0.01 | $3.67K | 367,061 |
| Carlos Moreira Chief Executive Officer, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −300 | $3.51 | $1.05K | 696,215 |
| John Charles O'Hara Chief Financial Officer, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −143 | $3.51 | $502 | 250,431 |
| John Charles O'Hara Chief Financial Officer, Director | Jun 3, 2026 | Sale(10b5-1 plan) | −5,582 | $3.53 | $19.70K | 250,574 |
| Jean-Pierre Enguent Vice President, R&DSS | Jun 3, 2026 | Sale(10b5-1 plan) | −15,000 | $3.51 | $52.65K | 0 |
| Carlos Moreira Chief Executive Officer, Director | Jun 3, 2026 | Sale(10b5-1 plan) | −7,005 | $3.53 | $24.73K | 696,515 |
| John Charles O'Hara Chief Financial Officer, Director | Jun 2, 2026 | Sale(10b5-1 plan) | −10,000 | $3.69 | $36.90K | 256,156 |
| Carlos Moreira Chief Executive Officer, Director | Jun 2, 2026 | Sale(10b5-1 plan) | −10,000 | $3.69 | $36.90K | 703,520 |
| Jean-Pierre Enguent Vice President, R&DSS | Jun 1, 2026 | Option exercise | +15,000 | $0.01 | $150 | 15,000 |
| Carlos Moreira Chief Executive Officer, Director | May 29, 2026 | Sale(10b5-1 plan) | −10,000 | $3.51 | $35.10K | 713,520 |
| John Charles O'Hara Chief Financial Officer, Director | May 29, 2026 | Sale(10b5-1 plan) | −10,000 | $3.51 | $35.10K | 266,156 |
| Carlos Moreira Chief Executive Officer, Director | May 27, 2026 | Sale(10b5-1 plan) | −4,139 | $3.50 | $14.49K | 723,520 |
| John Charles O'Hara Chief Financial Officer, Director | May 27, 2026 | Sale(10b5-1 plan) | −4,689 | $3.50 | $16.41K | 276,156 |
| Franck Jean Buonanno Vice-President, Global Sales | May 14, 2026 | Sale(10b5-1 plan) | −20,000 | $2.90 | $58.00K | 10,000 |
| Franck Jean Buonanno Vice-President, Global Sales | May 11, 2026 | Option exercise | +20,000 | $0.01 | $200 | 30,000 |
| Jean-Pierre Enguent Vice President, R&DSS | May 6, 2026 | Sale(10b5-1 plan) | −15,000 | $3.13 | $46.95K | 0 |
| Jean-Pierre Enguent Vice President, R&DSS | May 4, 2026 | Option exercise | +15,000 | $0.01 | $150 | 15,000 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 24, 2026 | Sale(10b5-1 plan) | −5,250 | $2.91 | $15.28K | 280,845 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 23, 2026 | Sale(10b5-1 plan) | −10,000 | $2.88 | $28.80K | 286,095 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 22, 2026 | Sale(10b5-1 plan) | −10,000 | $3.06 | $30.60K | 296,095 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 21, 2026 | Sale(10b5-1 plan) | −10,000 | $3.04 | $30.40K | 306,095 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 20, 2026 | Sale(10b5-1 plan) | −10,000 | $2.79 | $27.90K | 316,095 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 17, 2026 | Sale(10b5-1 plan) | −10,000 | $2.72 | $27.20K | 326,095 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 16, 2026 | Sale(10b5-1 plan) | −10,000 | $2.69 | $26.90K | 336,095 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 13, 2026 | Option exercise | +130,500 | $0.01 | $1.31K | 346,095 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 9, 2026 | Sale(10b5-1 plan) | −10,000 | $2.08 | $20.80K | 215,595 |
| Jean-Pierre Enguent Vice President, R&DSS | Apr 8, 2026 | Sale(10b5-1 plan) | −15,000 | $2.20 | $33.00K | 0 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 8, 2026 | Sale(10b5-1 plan) | −10,000 | $2.20 | $22.00K | 225,595 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 7, 2026 | Sale(10b5-1 plan) | −10,000 | $2.14 | $21.40K | 235,595 |
| Moreira Andreas Feuardent Chief Innovation Officer | Apr 7, 2026 | Sale(10b5-1 plan) | −10,000 | $2.31 | $23.10K | 0 |
| Moreira Andreas Feuardent Chief Innovation Officer | Apr 7, 2026 | Option exercise | +10,000 | $0.01 | $100 | 10,000 |
| Jean-Pierre Enguent Vice President, R&DSS | Apr 6, 2026 | Option exercise | +15,000 | $0.01 | $150 | 15,000 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 6, 2026 | Sale(10b5-1 plan) | −10,000 | $2.42 | $24.20K | 245,595 |
| John Charles O'Hara Chief Financial Officer, Director | Apr 2, 2026 | Sale(10b5-1 plan) | −10,000 | $2.45 | $24.50K | 255,595 |
| Franck Jean Buonanno Vice-President, Global Sales | Mar 31, 2026 | Sale(10b5-1 plan) | −10,000 | $2.35 | $23.50K | 10,000 |
| John Charles O'Hara Chief Financial Officer, Director | Mar 30, 2026 | Option exercise | +100,000 | $0.01 | $1.00K | 265,595 |
| Franck Jean Buonanno Vice-President, Global Sales | Mar 27, 2026 | Option exercise | +15,000 | $0.01 | $150 | 20,000 |
| John Charles O'Hara Chief Financial Officer, Director | Mar 25, 2026 | Sale(10b5-1 plan) | −10,000 | $2.92 | $29.20K | 165,183 |
| John Charles O'Hara Chief Financial Officer, Director | Mar 24, 2026 | Sale(10b5-1 plan) | −10,000 | $2.90 | $29.00K | 175,183 |
| John Charles O'Hara Chief Financial Officer, Director | Mar 23, 2026 | Sale(10b5-1 plan) | −10,000 | $2.99 | $29.90K | 185,183 |
| John Charles O'Hara Chief Financial Officer, Director | Mar 20, 2026 | Sale(10b5-1 plan) | −10,000 | $3.00 | $30.00K | 195,183 |
| John Charles O'Hara Chief Financial Officer, Director | Mar 19, 2026 | Sale(10b5-1 plan) | −10,000 | $3.02 | $30.20K | 205,183 |
| Nathalie Claude Odile Verjus Company Secretary | Mar 18, 2026 | Sale(10b5-1 plan) | −5,000 | $3.03 | $15.15K | 185,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sealsq's stock actually held short. Settlement fails (shares not delivered on time) peaked at 366,782 shares on Aug 31, 2026 over the last 90 days.
See a number that looks wrong?